 |
 |
【參考文獻】
1 Bosken CH，Harks J, Gatter K，et al. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocyto chemistry〔J〕.Am Re Respir Dis，1992；145:911.
2 Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis〔J〕. Novartis Found Symp，2001；234：419.
3 Churg A, Dal J, Tai H, et al. Tumor necrosis factorα is central to acute cigarette smokeinduced inflammation and connective tissue breakdown〔J〕. Am J Respir Crit Care Med, 2002;166(6):84954.
4 Sarah VC, Duncan FR, Pallav S, et al. Inspaired inhibition by dexamethasone of cytokine realease by alveolar macrophages from patients with chronic obstructive pulmonary disease〔J〕. Am J Respir Crit Care Med,2003;167:2431.
5 Retamales I, Elliott WM, Meshi B,et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection〔J〕.Am J Respir Crit Care Med,2001;164(3)：46973.
6 Lapperre TS, Posrma DS,Gosman MM,et al. Relation between duration of smoking cessation and bronchial inflammation in COPD〔J〕.Throax，2006；61(2):11521.
7 Verhoeven GT, Garrelds IM, Hoogsteden HC,et al. Effects of fluticasone propionate inhalation on level so far arachidonic acid metabolites in patient swit chronic obstructive pulmonary disease〔J〕. Mediators Inflamm, 2001;10(1):2266.
8 LI YH, Brauner A, Jonsson B, et al. Inhibition of macrophage proinflammatory cytokine express by steroids and recombinant IL10〔J〕. Biol Neonate, 2001；80(2)：12432.
9 van der Palen J, Monninkhof E, van der Valk P,et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease〔J〕.Thorax, 2006；61(1):2933.
10 Calverley PM,Boonsawat W,Cseke Z,et al.Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease〔J〕. Eur Respir J，2003；22(6):9129.
11 Gagnon YM, Levy AR, Spencer MD,et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and longacting beta2 agonists in a health maintenance organization〔J〕. Respir Med，2005;99(12):153445.
12 Nicho KL, Margolis KL,Wuorenma J,et al.The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community〔J〕.N Engl J Med，1994;331:77884.
13 Gamble E,Grootendorst DC,Brightling CE,et al. Antiinflammatory effects of the phosphon sphodiesterase4 inhibitor cilomilast (Airflo)in chronic obstructive pulmonary disease〔J〕.Am J Resp Crit Care Med, 2003;168：97682.
14 Rennard SI, Schachter N, Strek M, et al.Cilomilast for COPD：results of a 6month, placebocontrolled study of a potent, selective inhibitor of phosphodiesterase 4〔J〕.Chest，2006；129(1)：5666醫(yī).學(xué)全.在.線網(wǎng)站quanxiangyun.cn.
15 Corbel M, Noella G, Jerome L,et al.The selective phosphodiesterase 4 inhibitor RP73401 reduced matrix metalloproteinase 9 activity and transforming growth factorβ release during acute lung injury in mice: the role of the balance between tumor necrosis factorα and interleukin10〔J〕.Pharm Exp Ther，2002；301(1)：25865.
16 Alexandre T, Thomas H，Keller，et al. CGH2466，a combined adenosine receptor antagonist, p38 mitogenactivated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo antiinflammatory activities〔J〕. Brit J Pharm，2005；144: 100210.
17 Back M. Functional characteristics of cysteiny 12 leukotriene receptor subtypes〔J〕.Life Sci,2002;71:61122.
18 Dempsey OJ，Kennedy G, Lipworth BJ.Comparative efficacy and antiinflammatory profile of once daily therapy with leukotrieneant agonistor lowdose inhaled corticoster oid in patients with mild persistent asthma〔J〕.J Allergy Clin Immunol,2002;109(1)：6874.
19 Zühlke F,Kanniess K,Richter D,et al.Montelukast attenuates the airway response to hypertonic saline in moderatetosevere COPD〔J〕.Eur Respir J,2003；22：92630.
20 Ola M, Boveri B, Carlucci P, et al. Lung function improvement in smoker suffering from COPD with zafirlukast,a CysLT1 receptor antagonist〔J〕.Pulm Pharmacol Ther,2000；13:3015.
21 Rubinstein I,Kumar B, Schriever C. Longterm montelukast therapy in moderate to severe COPDa preliminary obvervation〔J〕. Respir Med，2004；98(2)：1348.
22 De Boer WI. Cytokines and therapy in COPD: a promising combination〔J〕. Chest，2002；121(3)：20918.
23 Spond J, Case N, Chapman RW,et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone〔J〕.Pulm Pharmacol Ther,2003；16(4)：20714.
24 Angshu BH, Terence AK, Rajmone JS,et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations〔J〕. Thorax，2000；55:11420.
25 Delacourt C,Herigault S,Delcau X, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPIHEN4,a new potent neutrophil elastase inhibitor〔J〕.Respir Cell Mol Boil,2006:2907.
26 Siemiatkowski A,Kosel J. Adhesion molecules and their rloe in organ response after traumol〔J〕.Pol Merkur Lekarski，2001；10(60):4658.
27 Basyigit I, Yildiz F, Ozkara SK, et al. The effect of clarithromycinon inflammatory markers in chronic obstructive pulmonary disease: preliminary data〔M〕.Ann Pharmacother，2004；38(9):14005.
